SUMMARY Antibodies to the ribonucleoprotein (RNP) component of extractable nuclear antigen were measured in patients with systemic lupus erythematosus (SLE) and other connective tissue subgroups by counterimmunoelectrophoresis. Antibodies to RNP were found in the sera of 32% of patients with a primary diagnosis of SLE, 29% of patients with features of SLE and erosive joint disease, none of 9 scleroderma patients, and in 75% of 8 patients with features of SLE and scleroderma. In the SLE patients overall there was an increased frequency of sclerodactyly and severe Raynaud's phenomenon in the patients with antibodies to RNP but no association of antibodies to RNP was found with the presence of erosive joint disease, Sjogren's syndrome, or the absence of renal disease in these patients.
Antibodies to ribonucleoprotein (RNP) have been shown hitherto in the sera of patients with a number of connective tissue diseases. The presence of high titres of antibodies to the RNP component of a saline extractable nuclear antigen (ENA) has been said to characterize a syndrome with distinctive clinical features and prognosis and given the name of 'mixed connective tissue disease' by Sharp et al. (1972) . Antibodies to RNP have also been shown in the sera of patients with systemic lupus erythematosus (SLE) and scleroderma in varying frequencies in different series and have been said to be associated with atypical features in these diseases (Parker, 1973; Kurata and Tan, 1976) . Most studies into the significance of these antibodies were carried out in the American continent. In our study we examined the frequency and clinical significance of these antibodies to RNP in patients with a primary diagnosis of SLE and of scleroderma, and in patients with features of SLE associated with an erosive arthritis or features of scleroderma. A counterimmunoelectrophoretic method was used to detect antibodies to RNP which has been shown to be a sensitive and rapid technique for detecting antibodies to different antigens (Kurata and Tan, 1976) .
Patients
The patients were categorized clinically before the results of the tests for RNP antibodies were known.
Sera of 63 patients with a primary diagnosis of SLE were examined. All but 2 of these satisfied three or more of the preliminary criteria of the American Rheumatism Association (ARA) (Cohen et al., 1971 ) for a diagnosis of SLE excluding the criterion related to the presence of LE cells. In addition they had positive antinuclear antibody tests at a titre of 1/32 or higher on serological testing using a standard immunofluorescent technique (Beck, 1961) . The remaining 2 patients had antinuclear antibodies and antibodies to native DNA as shown by the Farr test using E. coli native DNA as test antigen (Hughes, 1971 The frequency of positive serological tests for RNP antibodies in the 63 SLE patients was compared with their frequencies in 9 scleroderma patients, in 8 patients with features of both SLE and scleroderma, in 7 patients with features of SLE and erosive arthritis, and in 3 patients with features of polymyositis and scleroderma ( Table 2 ). 6 of the 9 scleroderma patients had typical gross generalized cutaneous involvement, and either gastrointestinal, cardiac, or pulmonary involvement. The other 3 had sclerodactyly in association with the calcinosis, Raynaud's phenomenon, and telangiectasia of the 'CRST' syndrome, and oesophageal involvement in one. None of the patients in this group had clinical features other than polyarthritis suggestive of SLE and none an acute febrile onset of their illness. Serological tests showed antinuclear factor positive at a titre of 1/64 or more in 7 of the 9 patients.
Eight patients were included in the group with features of both SLE and scleroderma (Table 3) . 6 had a primary diagnosis of SLE as discussed previously and were included in the group of 63 Sera were also examined from 3 patients with features of polymyositis with typical proximal muscle involvement, raised serum muscle enzyme, and muscle biopsy changes in association with features of scleroderma. The latter were oesophageal dilatation and absence of peristalsis particularly in the distal oesophagus, and tightness of facial skin around nose and mouth in all 3; and small bowel dilatation in 1. All 3 had Raynaud's phenomenon.
SJOGREN'S SYNDROME
The presence or absence of clinical Sjogren's syndrome was documented in all patients, and was diagnosed if either keratoconjuctivitis sicca (KCS) or xerostomia was present. KCS was diagnosed using standard criteria (Whaley et al., 1973) in the presence of subnormal Schirmer II tear test and punctate or filamentary keratitis seen after instillation of Rose-bengal into the conjunctival sac and with the aid of a slit lamp. Xerostomia due to Sjogren's syndrome was diagnosed in the presence of xerostomia on clinical examination, subnormal salivary flow rates for the age of the patient, and histological abnormalities greater than grade I on salivary labial gland biopsy (Whaley et al., 1973) . (Hughes, 1971) . Labelled E. coli native DNA was used as the test antigen and results were expressed as % DNA binding, the normal range being 0-30%.
RHEUMATOID FACTOR
Rheumatoid factor was estimated using latex particles coated with bovine gammaglobulin (Denver Laboratories).
STATI ST1CS
Statistical significances where mentioned were analysed using the x2 test with Yates's correction. Table 2 shows the frequency of antibodies to RNP in the sera of the different connective tissue groups. 32% of the 63 SLE patients overall and 29% of SLE patients with erosive arthritis had antibodies to RNP, while no antibodies were detected in the sera of the 9 scleroderma patients. 6 of the 8 patients with features of both SLE and scleroderma and 2 of the 3 with features of both polymyositis and scleroderma had antibodies to RNP. (Kurata and Tan, 1976) . 46% of the 50 SLE patients investigated by Kurata and Tan using this method were found to have antibodies to RNP, which is comparable to the 32% positive of SLE patients in this study. However, Kurata and Tan (1976) also found antibodies to RNP in the sera of 31 % of scleroderma patients, while the sera of all 9 of our scleroderma patients were negative. In our study a striking feature was the high frequency of antibodies to RNP in the sera of patients with features of both SLE and scleroderma and both polymyositis and scleroderma, which was in contrast to absent or low frequencies of antibodies in the other disease groups. Some of our patients seem to be similar to those described by Sharp et al. as having the 'MCTD' syndrome, although one of our patients with antibodies to RNP has active renal disease and another has epilepsy so that major organ involvement was seen in this group of patients.
Results
In our patients with a primary diagnosis of SLE, antibodies to RNP appeared to be associated with atypical disease features such as sclerodactyly or severe Raynaud's phenomenon but not with the absence of renal disease, Sj6gren's syndrome, erosive joint disease, nor with Raynaud's phenomenon. Thus our findings are in keeping with previous ones (Parker, 1972) , that antibodies to RNP in groups of patients with SLE are associated with an increased frequency of atypical features such as sclerodactyly or severe Raynaud's phenomenon. However, these results do not support the suggestion of Sharp et al. (1972) 
